Bayer's Courtroom Momentum Meets a Softer Quarter as Stivarga Heads for the Exit

Bayer's mRNA patent suits survive dismissal as a $7.25B Missouri settlement hangs in the balance; Q3 report due 3 November.

Two separate legal fronts are converging on Bayer at the same time, and the outcomes could matter more to the share price than anything happening in the company's labs. In the mRNA patent dispute, a US federal judge this week rejected motions from Pfizer, BioNTech and Moderna seeking early dismissal of infringement suits brought by Bayer CropScience. The ruling, first reported by Reuters, keeps the cases alive and forces the vaccine makers to answer the substance of the claims rather than walk away on procedure.

That decision carries weight beyond the courtroom. It underscores the strategic value of Bayer's intellectual property library, and if the patents hold up in later rounds, the company would gain real leverage in any licensing negotiation with the three defendants. What it does not do is settle the matter — the rejection of dismissal motions is not a final judgment, and patent litigation in the US typically grinds on for years before a verdict or a workable settlement emerges, with legal bills mounting along the way.

A Missouri Settlement Sits in the Balance

The second front is older and far more expensive. Roughly two weeks ago, a court in the US state of Missouri held a hearing on a proposed collective settlement that would see Bayer pay as much as USD 7.25 billion spread across 21 years. Should the judge reject the package or demand changes, the company faces the prospect of years of individual trials with damages that are impossible to model in advance.

Investors are therefore weighing two very different legal clocks: a patent case that could, in time, generate licensing income, and a settlement that could finally cap a long-running liability — or unravel entirely.

Portfolio Surgery Continues With Stivarga

While the lawyers work, management is quietly reshaping what Bayer actually sells. On 21 September the group agreed to sell its cancer drug Stivarga to the pharmaceutical company Grünenthal, in a deal worth up to EUR 375 million. Completion is targeted for the end of 2026 or early 2027. The disposal frees up cash and sharpens the focus of the remaining pipeline, and market watchers read it as evidence that leadership is systematically reviewing peripheral assets. The proceeds arrive at a moment when every euro of financial headroom counts toward debt reduction and strategic investment.

Smaller divestments of this kind provide targeted relief but barely move the needle on the scale of Bayer's balance-sheet obligations. The central question for shareholders is whether proceeds from deals like Stivarga, combined with operating cash flow, can meaningfully chip away at those legacy liabilities without hollowing out the earnings power of the pharmaceutical division.

Crop Science Carries the Quarter

The operating picture is decidedly mixed. In the second quarter of 2026, Bayer posted currency- and portfolio-adjusted revenue growth of 2.2 percent to EUR 10.872 billion, with the Crop Science agricultural unit doing the heavy lifting — its adjusted result climbed 30.2 percent. The pharma side moved the other way, with adjusted earnings there slipping 3.6 percent as patent expiries on key revenue drivers raised the pressure on newer products to perform.

One of those newer products just got a boost. On 17 September the US Food and Drug Administration approved a label expansion for the kidney drug Kerendia, clearing it for the treatment of chronic kidney disease in patients with type 1 diabetes. It is the first new therapeutic option in that indication for American patients in more than three decades.

Hitting the full-year target of adjusted EBITDA between EUR 9.6 billion and EUR 10.1 billion would go a long way toward validating the recovery story, particularly if the Missouri settlement is confirmed and the Stivarga sale closes on schedule.

What the Third Quarter Will Reveal

Near-term earnings remain the swing factor. Analyst Virginie Boucher-Ferte of Deutsche Bank Research painted a cautious picture of the upcoming interim report, forecasting operating revenue growth of just 1.3 percent year over year for the third quarter of 2026 alongside a 10 percent decline in operating profit. Those figures point to a core business still exposed to rising costs and weaker segments, and management will need to show that the profit drop is contained rather than the start of sustained margin erosion.

Deutsche Bank kept its Buy rating on the stock with a EUR 60 price target. Reaching that level would require both operational stabilization and credit for the pipeline's legal optionality. Bayer has already strengthened its financial position, raising EUR 2 billion through a hybrid bond issue a little over a week ago.

The shares closed the previous session down 3.3 percent at EUR 49.07, and they now sit 8.9 percent below their 52-week high — a gap that illustrates the upside available in the bull case. Since the start of the year, the stock has gained 33 percent and currently trades at EUR 49.19.

The Bear Case Has Not Gone Away

The risk of further margin deterioration is real and should not be discounted. The pessimistic scenario rests on the fear that the projected 10 percent profit decline marks the beginning of a longer slump in either the agricultural or pharmaceutical segment. US patent proceedings bring their own procedural uncertainty, and defendants can be expected to exhaust every defense to challenge the validity of the Bayer CropScience patents in the main action. If those claims fail or the protections are narrowed, the company would be left empty-handed — and combined with weakening operating results, that outcome would hit the share price hard.

Chart stability matters too. Defending the 50-day moving average of EUR 48.61, alongside management's commitment to full-year core earnings per share of EUR 4.30 to EUR 4.90, would keep the recovery intact and open additional financial room once Stivarga changes hands.

The next hard catalyst is dated: on 3 November, Bayer publishes its full interim report for the third quarter of 2026. That release will show whether the warnings of a 10 percent operating profit decline prove accurate or whether revenue holds up better than forecast. Until then, the US patent litigation remains an important but speculative counterweight to the fundamental challenges — and the Missouri judge's decision on the settlement package, followed by the Stivarga completion into early 2027, will shape how investors price the legal risks from here.